HLA antigen expression in melanocytic lesions: Is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? - 13/05/12
Reprint requests: Soldano Ferrone, MD, PhD, University of Pittsburgh Cancer Institute, 5117 Centre Ave, Pittsburgh, PA 15213.Abstract |
Background |
Although criteria are established for the histologic diagnosis of atypical nevi (AN), consensus about the criteria in the diagnosis of and in the definition of AN is limited. Moreover, intraobserver and interobserver differences in the application of these criteria for the diagnosis of AN have been observed.
Objective |
We sought to determine the usefulness of HLA antigen expression as a biomarker of AN.
Methods |
The immunoperoxidase reaction was used to mark common nevi and AN with HLA class I heavy chain–, β2microglobulin (β2m)-, and HLA class II β chain–specific monoclonal antibodies.
Results |
HLA class I heavy chain, β2m, and HLA class II β chain were expressed in 5 (8.6%) of the 58 common nevi and in 46 (
72%) of the 64 atypical melanocytic lesions. Among common lesions, only halo nevi expressed HLA class I heavy chain, β2m, and HLA class II β chain. The level of HLA class I heavy chain β2m and of HLA class II β chain expression correlated with the degree of cytologic atypia and architectural disorder.
Limitations |
The number of lesions tested and the subjective nature of the analysis of immunohistochemical staining of tissue sections are both limitations.
Conclusions |
The data presented suggest that HLA antigen expression is an objective biomarker that correlates well with the degree of cytologic atypia in AN and may: (1) be useful to distinguish common nevi from AN, and (2) represent a more objective measure to determine which AN should be excised.
Le texte complet de cet article est disponible en PDF.Key words : atypical nevus, cancer, classical HLA class I antigen, dysplastic nevus, HLA class II antigen, immune escape, immune surveillance, immunotherapy, melanocyte, melanoma, nevus
Abbreviations used : AN, β2m, IHC, mAb
Plan
| Supported by an American Society for Dermatologic Surgery Cutting Edge Research Grant (Dr Campoli) and by Public Health Service grants PO1CA109688, RO1CA104947 (Dr Ferrone), and RO1CA110249 (Dr Ferrone), awarded by the National Cancer Institute. |
|
| The studies described in this article were performed after approval by an institutional review board, approval number COMIRB 05-0309. |
|
| Conflicts of interest: None declared. |
|
| Please visit www.jaad.org for an unabridged version of this article. |
Vol 66 - N° 6
P. 911 - juin 2012 Retour au numéro
Article précédent
- Molecular profiling and gene expression analysis in cutaneous sarcoidosis: The role of interleukin-12, interleukin-23, and the T-helper 17 pathway
- Marc A. Judson, Richard M. Marchell, MaryAnn Mascelli, Alexa Piantone, Elliot S. Barnathan, Kevin J. Petty, Dion Chen, Hongtao Fan, Heidi Grund, Keying Ma, Frédéric Baribaud, Carrie Brodmerkel
- Integrating clinical/dermatoscopic findings and fluorescence in situ hybridization in diagnosing melanocytic neoplasms with less than definitive histopathologic features
- Beatrice Nardone, Mary Martini, Klaus Busam, Ashfaq Marghoob, Dennis P. West, Pedram Gerami
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?